IFNA1 and cancer: For example, PRR and IFN signaling in immune cells are immunostimulatory, while the same signaling in cancer cells drives cancer progression and immunotherapy resistance.1 Hence, a delivery system specific for immune cells is urgently needed for gene therapy targeting TME.